Today, personalized medicine advanced therapies play a pivotal role in the future of healthcare, an innovative breakthrough in personalized medicine that is shifting the paradigm in care delivery towards an exponentially more customized philosophy of healthcare delivery. These therapies harness the power of multidimensional patient data, such as clinical history, genomic sequences, proteomic and metabolomic profiles, epigenetic landscapes, and lifestyle to tailor interventions in a way that is optimal on an individual basis (maximizing efficacy and minimizing adverse effects). Technological advances that include second-generation sequencing techniques, high-throughput and omics, bioinformatics, and artificial intelligence have catalyzed the development of disease predispositions, molecular subtypes, and predictive biomarkers enabling custom patient stratification and treatment selections.

In oncology, advanced therapies include targeted drugs selected by biomarkers, immune checkpoint inhibitors, CAR-T cell therapies, gene editing, and oncolytic viral platforms and are better therapies in specific subsets of patients. Even with all these implementations, hurdles abound, such as the need to standardize large amounts of data, ethical and privacy issues, exorbitant healthcare costs and fair access. Advanced therapies bridge the gap between multi-omics and more sophisticated methods of therapy, offering a promising platform behind which effective and patient-oriented approaches to treatment may become a reality against a wide variety of diseases, becoming a paradigm of new healthcare transformation worldwide.